Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor

Inovio’s Voceryq will compete with a Precigen product that final 12 months grew to become the primary FDA-approved drug for recurrent respiratory papillomatosis, or RRP. Whereas the 2 immunotherapies carry the identical $460,000 record value, Inovio executives declare their product has one other aggressive benefit.

The submit Inovio’s DNA-Primarily based Immunotherapy Lands Speedy FDA Nod for Uncommon Kind of Tumor appeared first on MedCity Information.

Source link